Michael Fossel, MD, PhD Biogen’s recent news story regarding lecanemab is an example of how the field hasn’t changed. Although the data has yet to be made public, the claims parallel those of other drugs that have claimed efficacy in Alzheimer’s, such as solanezumab, aducanumab, etc. In each case, we see tantalizing statements, but the […]

Read more...